Berahyaluronidase Alfa Biosimilar – Hyaluronidase PH-20 – Research Grade

Description of Berahyaluronidase Alfa Biosimilar - Hyaluronidase PH-20 - Research Grade

Introduction

Berahyaluronidase Alfa Biosimilar, also known as Hyaluronidase PH-20, is a research grade enzyme that has been developed as a biosimilar to the human hyaluronidase PH-20 protein. This enzyme plays an important role in the breakdown of hyaluronic acid, a major component of the extracellular matrix in connective tissues. Berahyaluronidase Alfa Biosimilar has been extensively studied for its structure, activity, and potential therapeutic applications.

Structure of Berahyaluronidase Alfa Biosimilar

Berahyaluronidase Alfa Biosimilar is a glycoprotein enzyme that is composed of a single polypeptide chain of 354 amino acids. It has a molecular weight of approximately 40 kDa and is produced through recombinant DNA technology in a mammalian cell expression system. The primary structure of Berahyaluronidase Alfa Biosimilar is highly similar to the human hyaluronidase PH-20 protein, with a sequence identity of 96%. This ensures that the biosimilar has a similar three-dimensional structure and biological activity as the human protein.

The tertiary structure of Berahyaluronidase Alfa Biosimilar consists of a catalytic domain and a hyaluronan-binding domain. The catalytic domain contains the active site of the enzyme, which is responsible for the hydrolysis of hyaluronic acid. The hyaluronan-binding domain allows the enzyme to bind to hyaluronic acid, facilitating its breakdown. This unique structure of Berahyaluronidase Alfa Biosimilar makes it a highly specific and efficient enzyme for the degradation of hyaluronic acid.

Activity of Berahyaluronidase Alfa Biosimilar

The main activity of Berahyaluronidase Alfa Biosimilar is the breakdown of hyaluronic acid, a large polysaccharide molecule that is found in the extracellular matrix of connective tissues. This activity is achieved through the hydrolysis of the glycosidic bonds between the sugar units of hyaluronic acid, resulting in smaller fragments that can be easily metabolized and eliminated from the body. This process is crucial for tissue remodeling, wound healing, and other physiological processes.

Berahyaluronidase Alfa Biosimilar has been shown to have a similar enzymatic activity as the human hyaluronidase PH-20 protein. It has a high specificity for hyaluronic acid and does not degrade other glycosaminoglycans, ensuring minimal off-target effects. The enzyme has also been found to be stable and active in a wide range of pH and temperature conditions, making it suitable for various applications.

Therapeutic Applications of Berahyaluronidase Alfa Biosimilar

The ability of Berahyaluronidase Alfa Biosimilar to degrade hyaluronic acid has led to its potential use in various therapeutic applications. One of the main uses of this enzyme is in the treatment of tissue edema, which is characterized by an excess accumulation of fluid in tissues. By breaking down hyaluronic acid, Berahyaluronidase Alfa Biosimilar can improve tissue drainage and reduce swelling, making it a valuable tool in the treatment of conditions such as lymphedema and post-surgical edema.

Berahyaluronidase Alfa Biosimilar has also been studied for its potential use in facilitating the delivery of other therapeutic agents. The breakdown of hyaluronic acid by this enzyme can increase the permeability of tissues, allowing for better penetration of drugs and other molecules. This has potential applications in cancer therapy, where the enzyme can be used to enhance the delivery of chemotherapy drugs to tumor tissues.

Conclusion

Berahyaluronidase Alfa Biosimilar, also known as Hyaluronidase PH-20, is a research grade enzyme with a similar structure and activity as